To the best of our knowledge, the present study is the first to compare the clinical relevance of serum concentrations of CXCR2 and CXCR4 in relation to the well-established tumor marker (carcinoembryonic antigen–CEA) in PC patients and the marker of inflammation–C-reactive protein (CRP). Here, CXCR4 is linked to pachyonychia congenita.